Informed Consent Form
Drafts regulatory-compliant informed consent forms for healthcare procedures, clinical trials, research participation, or professional services. Incorporates HIPAA, FDA, IRB/Common Rule, and ICH-GCP requirements as applicable. Use when drafting surgical consent, research participant agreements, clinical trial consent, or treatment authorization forms.
Informed Consent Form
Drafts a defensible informed consent form satisfying disclosure obligations and documenting voluntary, knowing authorization.
Quick Start
Gather before drafting:
- Jurisdiction — which consent standard applies (professional, reasonable person, or subjective)
- Regulatory framework — HIPAA, FDA, IRB/Common Rule, ICH-GCP, state rules
- Procedure details — protocol, personnel, timeline, devices, medications
- Participant population — capacity issues, language needs, literacy level
- Institutional requirements — templates, mandatory language, formatting
Core Sections
1. Procedure Description
| Element | Include |
|---|---|
| Process overview | Prep, intervention, follow-up in plain language; define terms parenthetically |
| Timeline | Frequency, duration, total commitment |
| Personnel | Qualifications of those performing/supervising |
| Materials | Equipment, medications, devices with lay explanations |
| Participant burden | Physical demands, time, lifestyle changes, emotional impact |
2. Risk Disclosure and Benefits
Risk frequency tiers — use consistently:
| Tier | Frequency | Label |
|---|---|---|
| Common | >10% | "commonly" / "frequently" |
| Occasional | 1–10% | "occasionally" / "sometimes" |
| Rare | <1% | "rarely" |
| Isolated | Case reports only | "in isolated cases" |
For each material risk: nature of harm, severity, temporary vs. permanent, mitigation.
Benefits: realistic expectations only, no guarantees. State if experimental. Include statistical context when available.
3. Alternatives and Right to Refuse
- [ ] Each viable alternative with comparative risk/benefit/cost analysis
- [ ] Less invasive options and conservative management
- [ ] Option to decline — natural course explained factually
- [ ] No-coercion language: refusal won't cause abandonment or care loss
- [ ] If no alternatives exist, state clinical basis
4. Privacy and Information Governance
- [ ] Data collected, purpose, retention, access (care team, researchers, regulators)
- [ ] Applicable privacy framework (HIPAA, FERPA, state statutes)
- [ ] Confidentiality limits: mandatory reporting, court orders, safety exceptions
- [ ] Secondary uses require separate consent (QI, teaching, research, publication)
- [ ] Safeguards described; participant rights to access/correct data
- [ ] Certificate of Confidentiality status (research)
5. Participant Rights and Withdrawal
- [ ] Unconditional right to withdraw without penalty
- [ ] Withdrawal process: contact, written notice, data/specimen disposition
- [ ] Honest disclosure of practical limitations (irreversible steps, published aggregates)
- [ ] Right to ask questions at any point
- [ ] Contact info for questions, adverse events, complaints
- [ ] Financial transparency: covered costs, out-of-pocket, compensation
6. Signature and Execution Block
Include all that apply:
Primary participant — attestations: read/understood, opportunity to ask questions, voluntary consent. Signature, printed name, date.
Authorized representative (if participant lacks capacity) — signature, printed name, date, relationship, legal basis for authority.
Person obtaining consent — attestation that procedure was explained and participant demonstrated understanding. Signature, printed name/title, date.
Witness (when required by regulation/policy) — attestation of observing consent process. Signature, printed name, date.
Separate opt-in/opt-out blocks for each ancillary authorization:
- Photography/video
- Specimen use for future research
- Contact for additional studies
- Third-party information release
Document control footer: version number, effective date, supersedes date, page X of Y.
Include statement: participant receives a complete signed copy.
Drafting Rules
- Jurisdiction-first — confirm applicable consent standard before drafting; requirements vary by state
- Plain language — active voice, short sentences, common words; define technical terms parenthetically; 12pt minimum font
- Material risk standard — disclose any risk a reasonable person would consider significant; err toward over-disclosure
- No guarantees — use "may," "expected," "typical"; never promise outcomes
- Selective consent — participants must decline ancillary authorizations without affecting primary consent
- Capacity accommodations — address literacy, language, cognitive limitations in the attestation
Pitfalls
- Skipping jurisdictional analysis — consent standards differ significantly by state; a form valid in one may be inadequate in another
- Burying risks — material risks must be prominent, not hidden in dense paragraphs
- Coercive framing — refusal language must be neutral; never imply negative consequences for declining
- Missing withdrawal limits — state honestly which steps are irreversible; omission undermines defensibility
Final Check
- [ ] Applicable regulatory frameworks identified and addressed
- [ ] All material risks disclosed with frequency tier labels
- [ ] Alternatives section includes option to decline
- [ ] Privacy section covers confidentiality limitations
- [ ] Signature blocks match participant population (capacity, witnesses)
- [ ] Ancillary authorizations are separate opt-in/opt-out
- [ ] Document control footer with version, date, pagination
- [ ] Flag for review by legal counsel, compliance, and IRB/ethics committee (if research)
No additional documents ship with this skill.
Related Skills
Chart Audit Protocol
Drafts healthcare chart audit protocols covering clinical documentation review, coding accuracy, and billing compliance. Aligns with Medicare CoPs, O…
Clinical Trial Agreement
Drafts U.S. clinical trial agreements governing sponsor–site–investigator relationships under FDA rules (21 CFR Parts 50, 56, 312) and ICH-GCP E6(R2)…
Clinical Trial Investigator Agreement
Drafts U.S. clinical trial Investigator Agreements between sponsors/CROs and principal investigators or institutions for FDA-regulated drug, biologic…
Healthcare Corrective Action Plan
Drafts healthcare Corrective Action Plans (CAPs) responding to CMS survey deficiencies, Joint Commission findings, state inspection citations, or int…
Corrective Action Plan for Healthcare Deficiencies
Drafts a regulator-ready Corrective Action Plan (CAP) for U.S. healthcare facilities responding to inspection, survey, or audit deficiencies. Covers …